Tofacitinib in all Seasons: A Debate

Speciality: Emergency Medicine


Speaker:

Dr. Sauvik Das Gupta | Consultant Rheumatologist Yashoda Super Speciality Hospital Kaushambi

Dr. B D Pandey | Consultant Rheumatologist Fortis Hospital

Dr. Sakshi Mittal | Consultant Rheumatologist Max Hospital

Description:

A warm welcome to all the medical professionals in this interesting session on understanding the uses of tofacitinib in all seasons.

Tofacitinib, a potent Janus kinase (JAK) inhibitor, holds promise in treating various inflammatory conditions across all seasons. Its efficacy extends to managing rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, providing patients with relief from symptoms regardless of environmental changes. Moreover, its oral formulation offers convenience and flexibility, enabling consistent treatment adherence year-round.

With its versatile therapeutic benefits, tofacitinib stands as a reliable option for individuals battling chronic inflammatory diseases in every season. Its ability to target underlying inflammation allows patients to maintain stability in their conditions, ensuring uninterrupted quality of life despite seasonal fluctuations. As a result, patients can confidently navigate through different seasons with the assurance of effective symptom control and improved overall well-being.

Therefore, get an overall knowledge on understanding the uses of tofacitinib in all seasons. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer during young adulthood carries long-term mental toll, study finds

2.

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

3.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot